Interestingly, a phase 2 clinical trial evaluating the efficacy of systemic administration of a JAK1/TYK2 inhibitor is ongoing (NCT03715829) and will provide new insights into the physiopathology of vitiligo. This evidence concerns the gene TYK2 and vitiligo.